Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab - Related Studies

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

This study is ongoing, but not recruiting participants.

Study NCT00139841. Last updated on June 24, 2008. Information provided by Cephalon

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Non-Hodgkin's Lymphoma

2	Additional conditions recognized in this trial
		Lymphoma
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		Bendamustine HCl

5	Additional drug interventions recognized in this trial
		Bendamustine
		Nitrogen Mustard Compounds
		Rituximab

6	More general drug interventions related to this trial
		Alkylating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Immunologic Factors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Cephalon